First-line Treatment of HER2-positive Recurrent or Metastatic Breast Cancer
1 clinical trials · Condition
◉ Watch First-line Treatment of HER2-positive Recurrent or Metastatic Breast Cancer
| Record | Firm | Date |
|---|---|---|
| Efficacy and Safety of KN026 in Combination With HB1801 in the First-line Treatment of Subjects With HER2-positive Recurrent or Metastatic Breast Cancer. (NCT05838066) | Shanghai JMT-Bio Inc. | 2023-07-23 |
Track First-line Treatment of HER2-positive Recurrent or Metastatic Breast Cancer automatically
Every clearance here is in the API, with alerts when new ones post.